Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Nykode Therapeutics ASA
ASA
Active
Org 990646066
Gaustadalleen 21, 0349
Oslo
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2007 · 19 years old
47 employees
www.nykode.com
Monitor
Share
Norway
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Nykode Therapeutics ASA
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
NOK millions
269M
202M
134M
67M
0M
2020: 216M
216M
2020
2021: 36M (-83% vs 2020)
36M
-83%
2021
2022: 9M (-75% vs 2021)
9M
-75%
2022
2023: 13M (+44% vs 2022)
13M
+44%
2023
2024: 9M (-31% vs 2023)
9M
-31%
2024
EBITDA
NOK millions
255M
159M
62M
-35M
-131M
2020: 179M
179M
2020
2021: -9M (-105% vs 2020)
-9M
-105%
2021
2022: -50M (-456% vs 2021)
-50M
-456%
2022
2023: -55M (-10% vs 2022)
-55M
-10%
2023
2024: -44M (+20% vs 2023)
-44M
+20%
2024
Income statement
NOK thousands
Item
2024
2023
2022
2021
2020
Revenue
9 158
13 362
9 029
35 766
215 695
Staff expenses
−19 741
−18 331
−11 771
−14 459
−0
EBITDA
−43 709
−54 533
−50 482
−9 205
178 568
Depreciation & amort.
−2 039
−1 947
−1 666
−711
−303
EBIT
−45 748
−56 480
−52 148
−9 916
178 265
Net financials
547
14 051
2 148
−412
2 639
Profit before tax
−45 201
−42 429
−50 000
−10 328
180 904
Tax
−6 722
−9 037
−8 320
−1 731
−0
Net profit
−38 479
−33 392
−41 680
−8 597
149 774
Balance sheet
NOK thousands
Item
2024
2023
2022
2021
2020
Total assets
156 082
210 353
223 706
265 755
230 028
Equity
140 142
174 832
158 826
194 866
178 850
Long-term debt
7 857
15 664
25 444
35 219
37 997
Short-term debt
8 083
19 855
39 406
30 754
13 181
Total debt
15 940
35 519
64 850
65 973
51 178
Financial ratios
5-year trend
EBITDA margin
−477,3 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2020
2024
Equity ratio
89,8 %
This company
38,2 %
Market median
This company
Market median
135% above market
2020
2024
Return on equity
−27,5 %
This company
18,4 %
Market median
This company
Market median
249% below market
2020
2024
Net profit margin
−420,2 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2020
2024
Asset turnover
0,06×
This company
1,12×
Market median
This company
Market median
95% below market
2020
2024
Debt / equity
0,11×
This company
0,62×
Market median
This company
Market median
82% below market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
View
PDF
More on Nykode Therapeutics ASA
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
